Treillières, France

Nicolas Poirier

This inventor holds 24 USPTO granted patents and 29 published patent applications, plus 2 CIPO patents and 16 EPO patents, primarily in Immunotherapy Antibodies. Top assignees: Ose Immunotherapeutics, National Institute of Health and Medical Research, The University of Nantes. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicolas Poirier. Retrieved from https://idiyas.com/inventor/nicolas-poirier

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 24 

% Patents Active = 95.8

 

 

Average Co-Inventor Count = 3.8

ph-index = 3

Forward Citations = 33(Granted Patents)


Location History:

  • Nantes, FR (2017)
  • Treillières, FR (2014 - 2022)
  • Treillieres, FR (2016 - 2024)

Company Filing History:


Years Active: 2014-2026

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Chimeric Antigen Receptors
Anti-Chemokine Receptor
Humanized Antibodies
CD127
SIRPa
Cancer Treatment
T-Cell Response
Therapeutic Applications
Biomarkers
Polypeptides
IL7 Receptor
Antagonist
24 patents (USPTO):Explore Patents

Title: Innovations by Inventor Nicolas Poirier

Introduction

Nicolas Poirier, a prominent inventor based in Treillières, France, has made significant contributions in the field of medical innovation. With a remarkable total of 16 patents, he has dedicated his work to advancing treatments for various health conditions, particularly in immunotherapy and inflammatory diseases.

Latest Patents

Among his latest patents is a groundbreaking method for promoting a T-cell response or treating cancer by administering an antagonist to the human C-type lectin-like receptor-1 (CLEC-1). This invention details methods for enhancing T cell responses by investigating the expression and function of CLEC-1 in human dendritic cells. The research presents evidence that disruption of the CLEC-1 signaling enhances T cell activation, particularly in the context of Th17 and Th1 cells.

Another noteworthy patent focuses on biomarkers for assessing the response status for the treatment of inflammatory conditions affecting the digestive tract, such as inflammatory bowel disease. This invention identifies specific biomarkers to evaluate whether patients are responsive to treatments using anti-TNFalpha or anti-α4β7 agents. The methods outlined can assist in determining the effectiveness of these treatments in human patients suffering from conditions like Ulcerative Colitis or Crohn's disease.

Career Highlights

Nicolas Poirier has built his career at the intersection of research and practical application within the medical field. He has collaborated with reputable organizations such as Ose Immunotherapeutics and the Institut National de la Santé et de la Recherche Médicale, contributing his expertise to the development of innovative therapeutic solutions.

Collaborations

Throughout his career, Nicolas has worked closely with notable colleagues, including Caroline Mary and Bernard Vanhove. Their collaborative efforts have been instrumental in pushing forward research that aims to change the landscape of treatments for immune-related conditions and diseases.

Conclusion

Nicolas Poirier's inventive work and continuous pursuit of innovation in medical treatments showcase his commitment to improving patient care. His extensive portfolio of patents reflects his dedication and the impact of his contributions to the fields of immunotherapy and inflammatory disease treatment. With each innovation, he plays a vital role in advancing medical science and improving health outcomes for patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…